Newton and ABB Labs Enter Partnership to Expand Access to Lens Portfolio in US

Newton announced that it has selected ABB Labs, an independent optical laboratory network, as a strategic laboratory partner. The collaboration aims to expand access to Newton’s lens portfolio across the United States.

According to Newtown (formerly Neurolens), through this strategic vendor partnership, thousands of additional independent eye care practices will gain access to Newton’s technologies, including Neurolens and Sequel. The partnership leverages ABB Labs’ US-based laboratory footprint and its long-standing relationships with independent optometry, enabling broader availability and efficient delivery of Newton’s solutions. Financial terms of the deal were not disclosed. 

Newton’s Neurolens features patented Contoured Prism technology, which is designed to provide relief from symptoms associated with eye misalignment, including headaches, neck pain, and motion sickness. Sequel, Newton’s everyday lens, incorporates proprietary Convergence Boost technology to deliver enhanced visual comfort and clarity both on digital screens. Sequel lenses have recently become available through VSP coverage, making Convergence Boost technology accessible to millions of patients nationwide.

“This partnership represents a transformative moment in our ability to serve independent optometry,” said Davis Corley, CEO of Newton. “ABB Labs doesn’t just expand our manufacturing capacity—it multiplies our reach across the United States. ABB’s scale and reputation will strengthen our existing Newton lab network and support continued product availability, quality, and service for our growing customer base.”

Newton’s Neurolens and Sequel lenses are now available to order through ABB Labs. Eye care professionals can learn more and get started by clicking here.

Originally published online on Eyewire+.